Clinical Trial Update: A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of Walvax's PCV13-TT compared with Pfizer's PCV13 (Prevnar 13); study is currently active but not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease

Drugs mentioned

• PCV13-TT (Pneumococcal conjugate vaccine 13-valent with tetanus toxoid carrier protein)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Walvax Biotechnology Co., Ltd. | Conditions: Pneumococcal Disease, Invasive | Phase 3 | Status: ACTIVE_NOT_RECRUITING